||ORD SHS 10P
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals Share Discussion Threads
Showing 551 to 574 of 575 messages
|Latest Broker forecast:-
JP Morgan Cazenove - 28/03 - Reiterates Neutral - 2,400.00p|
|Extremely difficult to predict. It could drift lower or it could suddenly announce some new drug or treatment, and shoot back up again. Personally I doubt whether it would drift lower than 1800, and if it did then the Directors would probably start buying again. But who knows.....|
|Purchased HIK from Sept - Dec, had to average down, due to catching a falling knife.
Decided to sell day before earnings as I had a funny feeling, glad I did now!.
Watching from the sidelines, I think It will slip to 1600-1800 again over the next few months, then will happily buy in again.|
|Spoke too soon - they seem to have popped back over the 2000 line at close of play! I'm off to open a magnum of champagne...................not!|
|Below 2000 as predicted/expected. The test will be how they perform Monday and the rest of next week. Difficult to tell.|
|Arrgghhh! Bought back into these too soon after the early falls from the spike and now paying a heavy penalty! As karateboy commented, the sale by Bassam Kanaan of 43,000 at £21.22 doesn't help at all. I note that there have been no purchases by Darhold Ltd (the main director management company) since they last bought at £18.28 on 16 December.
Shardview - I don't think HIK will fall below say 1850 at the worst, but they seem set on testing 2000 for the moment. Of the current Broker forecasts, the lowest is HSBC at 1800. Others are 2400, 2630 etc - see below:-
JP Morgan Cazenove 21/03 Reiterates Neutral to Neutral 2,400.00p
Peel Hunt 17/03 Reiterates Buy to Buy 2,630.00p
HSBC 17/03 Downgrades Hold to Reduce 1,800.00p
JP Morgan Cazenove 16/03 Downgrades Overweight to Neutral 2,400.00p
Peel Hunt 15/03 Reiterates Buy to Buy 2,340.00p
Cantor Fitzgerald 15/03 Reiterates Buy to Buy 2,500.00p
JP Morgan Cazenove 13/03 Reiterates Overweight to Overweight
Numis 10/03 Downgrades Buy to Add 2,350.00p
Suggest you "keep powder dry" to see what happens tomorrow, and reassess position if they go below 2000 - which seems quite possible!
Other comments:- British Bulls says "Stay in Cash".
FT says "As of Mar 20, 2017, the consensus forecast amongst 12 polled investment analysts covering Hikma Pharmaceuticals Plc advises that the company will outperform the market.".
I definitely think they will come back, but the question is how far might they fall before they come back??? See what happens tomorrow and perhaps look for any further comment over the weekend.
Finally, Shardview, XAR has not produced the goods for me at present and neither (today) has RRS. Distinguished myself by having my top 3 holdings in the top FTSE 100 fallers. Roll on tomorrow........please!|
|Loads of buys going through as sells including my own. Doesn't help.|
|i looking to buy in at below 18 again of course depends on how fast they fall as they fallen faster than expected as some said before this share not for the faint hearted|
|You've got to love these shares! They don't mess about. Seems to be very little rationale. I've just sold my IMB shares(purchased @ 33.80) in prep for buying heavily back into Hikma. Fez, you must be happy with your XAR holding! They're a bit too volatile for me! So, any opinions on where Hikma might bottom out? I'd find it tough to resist 1950, but they made 1575 last time. What I really don't understand is how they can fall so far after such a reaction to the results!|
|This may explain the recent falls. A Director sold 43000 shares last few days.|
|Yes, you did well there.|
|I buy again if goes below 20 the question then at what price think that 18 be nice but glad i sold out on results day.|
|Yeah - I just bought again! Fingers crossed!!!!!|
|Hi FP - yes it is dipping. I am presently deciding whether to add......
Some conflicting broker forecasts and press views. Peel Hunt says Buy and estimates 2630 while HSBC says Reduce and estimates 1800. Quite a wide divergence!!
Ex-div on 6 April and I suspect there will be support before then. A difficult decision - perhaps the Directors will show their hand again??
British Bulls latest recommendation is to Buy:- "Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 2,154.0000, and our valid average buying price stands now at 2,157.0000. The previous SELL signal was issued on 14/03/2017, 3 days ago, when the stock price was 2,126.0000. Since then HIK.L has risen by +1.46%.Market Outlook A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed and a BUY signal is generated. Market wants to reward the bulls. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd."|
|@Fezz77: Opened a SB on this on Friday when it hit -1.7% for the second time on what looked look a good entry point on the rise then pullback after results, liking the tip... tomorrow should bode well, if it dips tomorrow (stranger things have happened) I will add.|
|Tipped in The Times today, share of the week.|
|JP Morgan forecast is "neutral" - 2400
What is Barclays forecast?|
|jp Morgan bearish. Barclays bullish.|
|Big difference between HSBC forecast - 1800, and Peel Hunt forecast - 2630.
Others at 2340, 2400 and 2500.
I'd be confident/happy with 2300.|
|Joel - no idea how dip occurred but price seems to have recovered somewhat. Odd things can happen between 8 and 8.30!!
Shardview - nice to be back in here again! Hope its all worthwhile.....
Broadwood - are you a long term holder? Any views on future prospects?|
|Why was there such a big dip in the morning?|
|Hikma Pharmaceuticals provided a tonic for the main share index on Wednesday, with shares in the company up 7% after it reported lower profits but better sales and hiked the dividend.
On revenue up 39% to $1.95bn over the calendar year, the FTSE 100 drug maker generated statutory operating profits of $302m, which were down 21% on the previous year, though excluding exceptional items like acquisition costs, goodwill amortisation and inventory adjustments, core operating profits were up 2% to $419m.
Profits before tax fell 34% to $210m but core profits were boosted by strong growth in injectables and branded drugs, which was offset by a decline at the generics business as it integrated last February's $1.7bn acquisition of specialty generics company West-Ward Columbus and more than doubled its investment in research and development across the group.|
|Sold out this morning did well as only held it for 5 months rather take the cash and come latter if goes down|